Abstract
Vaccination against rotavirus disease has been a global preventive health priority since rotaviruses were first discovered in the 1970s. The first licensed rotavirus vaccine, RRV-TV, was removed from the market shortly after licensure because of an unexpected serious adverse event, intussusception. A pentavalent rotavirus vaccine, PRV, is the second FDA-licensed rotavirus vaccine and does not signal the risk observed with RRV-TV. The properties and large safety study results of PRV are reviewed here.
MeSH terms
-
Diarrhea, Infantile / immunology
-
Diarrhea, Infantile / prevention & control
-
Diarrhea, Infantile / virology
-
Drug-Related Side Effects and Adverse Reactions
-
Humans
-
Immunization / methods*
-
Infant
-
Intussusception
-
Rotavirus / immunology*
-
Rotavirus Infections / immunology
-
Rotavirus Infections / prevention & control*
-
Rotavirus Infections / virology
-
Rotavirus Vaccines / adverse effects
-
Rotavirus Vaccines / immunology
-
Rotavirus Vaccines / therapeutic use*
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / immunology
-
Vaccines, Attenuated / therapeutic use*
Substances
-
RotaTeq
-
Rotavirus Vaccines
-
Vaccines, Attenuated